Malignant hyperthermia;L'hyperthermie maligne

Revue Medicale de la Suisse Romande

Volumn 119, Issue 3, 1999, Pages 191-202

  Chastonay, Pierre ^a   Bracco, David ^a   Freymond, Daniel ^b   Ravussin, Patrick ^a  

^a Hopital Regional   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; ANTIPYRETIC ANALGESIC AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BICARBONATE; CALCIUM; CATECHOLAMINE DERIVATIVE; CYCLOPROPANE; DANTROLENE; DECAMETHONIUM; DIGITALIS; DROPERIDOL; ETOMIDATE; FENTANYL; HALOTHANE; INHALATION ANESTHETIC AGENT; KETAMINE; LOCAL ANESTHETIC AGENT; MANNITOL; METHYLXANTHINE; NEUROMUSCULAR DEPOLARIZING AGENT; NITRATE; OPIATE; PARACETAMOL; PHENOTHIAZINE; PROPOFOL; RYANODINE RECEPTOR; SUXAMETHONIUM; UNINDEXED DRUG;

ANESTHESIA COMPLICATION; CALCIUM CELL LEVEL; CLINICAL FEATURE; DIAGNOSTIC APPROACH ROUTE; DISEASE ASSOCIATION; DUCHENNE MUSCULAR DYSTROPHY; GENE; HUMAN; HYPERMETABOLISM; HYPERTHERMIA; INFANT; INHALATIONAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALIGNANT HYPERTHERMIA; MORBIDITY; MORTALITY; MUSCLE RIGIDITY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; REVIEW; SCORING SYSTEM;

BIOPSY; CHILD, PRESCHOOL; DANTROLENE; DISEASE MODELS, ANIMAL; HUMANS; MALE; MALIGNANT HYPERTHERMIA; MASS SCREENING; MUSCLE RELAXANTS, CENTRAL; PRACTICE GUIDELINES; RISK FACTORS; SEVERITY OF ILLNESS INDEX;

EID: 0032953358     PISSN: 00353655     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (49)

1. Denborough M.A., Lovell R.R.H.: Anaesthetic death in a family. Lancet, 2:45, 1960.
2. Denborough M.A., Forster J.F.A., Lovell R.R.H. et al.: Anesthesia death in a family. Br. J. Anaesth., 34: 395-398, 1962.
3. Hall L.W., Woolf N., Bradley J.W., Jolly D.W.: Unusual reaction to suxamethonium chloride. Br. Med. J., 2 (525):1305, 1966.
4. Gonzalez L.E., Melendez-Vasquez C.V., Gregson N.A. et al.: A rat model of spontaneous myopathy and malignant hyperthermia. Am. J. Pathol., 152: 1099-1103, 1998.
5. Kalow W., Britt B.A., Terreau M.E., Haist C.: Metabolic error of muscle metabolism after recovery from malignant hyperthermia. Lancet, 2 (7679): 895-898, Oct. 31, 1970.
6. Chan T.C., Evans S.D., Clark R.F.: Drug-induced hyperthermia. Crit. Care Clin., 13: 785-808, 1997.
7. Bendixen D., Skovgaard L.T., Ording H.: Analysis of anaesthesia in patients suspected to be susceptible to malignant hyperthermia before diagnostic in vitro contracture test. Acta Anaesthesiol. Scand., 41: 480-484, 1997.
8. Robinson R.L., Monnier N., Wolz W. et al.: A genome wide search for susceptibility loci in three European malignant hyperthermia pedigrees. Hum. Mol. Genet., 6: 953-961, 1997.
9. Robinson R., Curran J.L., Hall W.J. et al.: Genetic heterogeneity and HOMOG analysis in British malignant hyperthermia families. J. Med. Genet., 35: 196-201, 1998.
10. Harwood T.N., Nelson I.E.: Massive postoperative rhabdomyolysis after uneventful surgery: a case report of subclinical malignant hyperthermia. Anesthesiology, 88: 265-268, 1998.
11. O'Flynn R.P., Shutack J.G., Rosenberg H., Fletcher J.E.: Masseter muscle rigidity and malignant hyperthermia susceptibility in pediatric patients. An update on management and diagnosis. Anesthesiology, 80: 1228-1233, 1994.
12. Morrison A.G., Serpell M.G.: Malignant hyperthermia during prolonged surgery for tumour resection. Eur. J. Anaesthesiol., 15: 114-117, 1998.
13. Kozak-Ribbens G., Bendahan D., Rodet L. et al.: Metabolic events with spontaneous malignant hyperthermia crisis in an anaesthetized pig. Can. J. Anaesth., 44: 757-764, 1997.
14. Fierobe L., Nivoche Y., Mantz J. et al.: Perioperative severe rhabdomyolysis revealing susceptibility to malignant hyperthermia. Anesthesiology, 88: 263-265, 1998.
15. Laurence A.S., Vanner G.K., Collins W. et al.: Serum and urinary myoglobin following an aborted malignant hyperthermia reaction. Anaesthesia, 51:958-961, 1996.
16. Larach M.G., Rosenberg H., Gronert G.A. et al.: Hyperkalemic cardiac arrest during anesthesia in infants and children with occult myopathies. Clin. Pediatr. (Phila) 36: 9-16, 1997.
17. Larach M.G., Localio A.R., Allen G.C., Denborough M.A., Fllis F.R., Gronert G.A., Kaplan R.F., Muldoon S.M., Nelson I.E., Ording H. et al.: A clinical grading scale to predict malignant hyperthermia susceptibility. Anesthesiology, 80: 771-779, 1994.
18. MacLennan D.H., Phillips M.S.: Malignant hyperthermia. Science 256: 789-794, 1992.
19. Loke J., MacLennan D.H.: Malignant hyperthermia and central core disease: disorders of Ca 2+ release channels. Am. J. Med. 104: 470-486, 1998.
20. Reber A., Schumacher P., Urwyler A.: Effects of three different types of management on the elimination kinetics of volatile anaesthetics. Implications for malignant hyperthermia treatment. Anaesthesia, 48: 862-865, 1993.
21. Palnitkar S.S., Mickelson J.R., Louis CF. et al.: Pharmacological distinction between dantrolene and ryanodine binding sites: evidence from normal and malignant hyperthermia-susceptible porcine skeletal muscle. Biochem. J., 326: 847-852, 1997.
22. Pollock N.A., Langton E.E.: Management of malignant hyperthermia susceptible parturients. Anaesth. Intensive Care, 25: 398-407, 1997.
23. Monsieurs K.G., Van Broeckhoven C., Martin J.J. et al.: Gly341Arg mutation indicating malignant hyperthermia susceptibility: specific cause of chronically elevated serum creatine kinase activity. J. Neurol. Sci., 154: 62-65, 1998.
24. Weglinski M.R., Wedel D.J., Engel A.G.: Malignant hyperthermia testing in patients with persistently increased serum creatine kinase levels. Anesth. Analg., 84: 1038-1041, 1997.
25. Zukowski F., De Craemer D., Van den Branden C. et al.: An image analysis study of vastus lateralis muscle fibers in malignant hyperthermia susceptible patients. Clin. Neuropathol., 17: 6-11, 1998.
26. Mezin P., Payen J.F., Bosson J.L. et al.: Histological support for the difference between malignanthyperthermia susceptible (MHS), equivocal (MHE) and negative (MHN) muscle biopsies. Br. J. Anaesth., 79: 327-331, 1997.
27. Fagerlund T.H., Ording H., Bendixen D. et al.: Discordance between malignant hyperthermia susceptibility and RYR1 mutation C1840T in two Scandinavian MH families exhibiting this mutation. Clin. Genet., 52: 416-421, 1997.
28. Hopkins P.M., Hartung E., Wappler F.: Multicentre evaluation of ryanodine contracture testing in malignant hyperthermia. The European Malignant Hyperthermia Group. Br. J. Anaesth., 80: 389-394, 1998.
29. Allen G.C., Larach M.G., Kunselman A.R.: The sensitivity and specificity of the caffeine-halothanecon-tracture test: a report from the North American Malignant Hyperthermia Registry. The North American Malignant Hyperthermia Registry of MHAUS. Anesthesiology, 88: 579-588, 1998.
30. Ording H., Brancadoro V., Cozzolino S. et al.: In vitro contracture test for diagnosis of malignant hyperthermia following the protocol of the European MH Group: results of testing patients surviving fulminant MH and unrelated low-risk subjects. The European Malignant Hyperthermia Group (see comments). Acta Anaesthesiol. Scand, 41: 955-966, 1997.
31. Ording H., Glahn K., Gardi T. et al.: 4-Chloro-m-cresol test-a possible supplementary test for diagnosis of malignant hyperthermia susceptibility. Acta Anaesthesiol. Scand., 41: 967-972, 1997.
32. Gilly H., Musat I., Fricker R. et al.: Classification of malignant hyperthermia-equivocal patients by 4-chloro- M-cresol. Anesth. Analg., 85: 149-154, 1997.
33. Gronert G.A.: Testing for MH susceptibility. Acta Anaesthesiol. Scand., 41: 953-954, 1997.
34. Fagerlund T.H., Islander G., Ranklev Twetman E. et al.: Malignant hyperthermia susceptibility, an autosomal dominant disorder? Clin. Genet., 51: 365-369, 1997.
35. Ummenhofer W., Roesslein R., Suffer P.M. et al.: Muscle biopsy for malignant hyperthermia screening in children. Eur. J. Pediatr. Surg., 7: 259-262, 1997.
36. Medina K.A., Mayhew J.F.: Generalized muscle rigidity and hypercarbia with halothane and isoflurane. Anesth. Analg., 86: 297-298, 1998.
37. Celebioglu B.: A case of suspected malignant hyperthermia during desflurane administration. Anesth. Analg., 86: 916, 1998.
38. Allen G.C., Brubaker C.L.: Human malignant hyperthermia associated with desflurane anesthesia. Anesth. Analg., 86: 1328-1331, 1998.
39. Michalek-Sauberer A., Fricker R., Gradwohl I. et al.: A case of suspected malignant hyperthermia during desflurane administration. Anesth. Analg., 85: 461-462, 1997.
40. Kasamatsu Y., Osada M., Ashida K. et al.: Rhabdomyolysis after infection and taking a cold medicine in a patient who was susceptible to malignant hyperthermia. Intern. Med., 37: 169-173, 1998.
41. Kochling A., Wappler F., Winkler G. et al.: Rhabdomyolysis following severe physical exercise in a patient with predisposition to malignant hyperthermia. Anaesth. Intensive Care, 26: 315-318, 1998.
42. Kojima Y., Oku S., Takahashi K. et al.: Susceptibility to malignant hyperthermia manifested as delayed return of increased serum creatine kinase activity and episodic rhabdomyolysis after exercise. Anesthesiology, 87: 1565-1567, 1997.
43. Ryan J.F., Tedeschi L.G.: Sudden unexplained death in a patient with a family history of malignant hyperthermia. J. Clin. Anesth., 9: 66-68, 1997.
44. Graham G.E., Silver K., Arlet V., Der Kaloustian V.M.: King syndrome: further clinical variability and review of the literature. Am. J. Med. Genet., 78: 254-259, 1998.
45. DeCauwer H., Heytens L., Lubke U. et al.: Discordant light microscopic, electron microscopic, and in vitro contracture study findings in a family with central core disease. Clin. Neuropathol., 16: 237-242, 1997.
46. Bertorini T.E.: Myoglobinuria, malignant hyperthermia, neuroleptic malignant syndrome and serotonin syndrome. Neurol. Clin., 15: 649-671, 1997.
47. Pennings E.J., Verkes R.J., de Koning J. et al.: Tranylcypromine intoxication with malignant hyperthermia, delirium, and thrombocytopenia. J. Clin. Psychopharmacol., 17: 430-432, 1997.
48. Tsujimoto S., Maeda K., Sugiyama T. et al.: Efficacy of prolonged largedose dantrolene for severe neuroleptic malignant syndrome. Anesth. Analg., 86: 1143-1144, 1998.
49. Miyatake R., Iwahashi K., Matsushita M. et al.: No association between the neuroleptic malignant syndrome and mutations in the RYR1 gene associated malignant hyperthermia. J. Neurol. Sci., 143: 161-165, 1996.